The role of platelets in sepsis

Thrombosis and Haemostasis

Volumn 112, Issue 4, 2014, Pages 666-677

  de Stoppelaar, Sacha F ^a   van 't Veer, Cornelis ^a   van der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Infectious diseases; Inflammatory mediators; Platelet immunology

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; CLOPIDOGREL; DIPYRIDAMOLE; PADGEM PROTEIN; PLASMA PROTEIN; PROTEINASE ACTIVATED RECEPTOR; THROMBOCYTE FACTOR 4; TICAGRELOR; TICLOPIDINE; TOLL LIKE RECEPTOR; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1;

ARTICLE; BLOOD CLOTTING; CELL INTERACTION; ENDOTHELIUM; HEMOSTASIS; HUMAN; IMMUNITY; INFLAMMATION; INFLAMMATORY CELL; KIDNEY INJURY; LUNG INJURY; META ANALYSIS (TOPIC); MICROTHROMBUS; MULTIPLE ORGAN FAILURE; NONHUMAN; PLATELET MICROPARTICLE; PROGNOSIS; SEPSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ACUTE LUNG INJURY; ANIMAL; BLOOD; CYTOLOGY; DISSEMINATED INTRAVASCULAR CLOTTING; IMMUNOLOGY; INNATE IMMUNITY; LEUKOCYTE; METABOLISM; THROMBOSIS;

ACUTE LUNG INJURY; ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; DISSEMINATED INTRAVASCULAR COAGULATION; ENDOTHELIUM; HEMOSTASIS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LEUKOCYTES; PLATELET ACTIVATION; SEPSIS; THROMBOSIS;

EID: 84908554286     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-02-0126     Document Type: Article

References (121)

1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013; 369: 840-851.
2. Hotchkiss RS, et al. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13: 260-268.
3. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38 (2 Suppl): S26-34.
4. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13: 34-45.
5. Semple JW, et al. Platelets and the immune continuum. Nat Rev Immunol 2011; 11: 264-274.
6. Schouten M, et al. Inflammation, endothelium, and coagulation in sepsis. J Leukocyte Biol 2008; 83: 536-545.
7. Vieira-de-Abreu A, et al. Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immunopathol 2012; 34: 5-30.
8. Yeaman MR. Platelets in defense against bacterial pathogens. Cell Mol Life Sci 2010; 67: 525-544.
9. Morrell CN, et al. Emerging roles for platelets as immune and inflammatory cells. Blood 2014; Epub ahead of print.
10. Gawaz M, et al. Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med 1997; 23: 379-385.
11. Russwurm S, et al. Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 2002; 17: 263-268.
12. Sakamaki F, et al. Soluble form of P-selectin in plasma is elevated in acute lung injury. Am J Resp Crit Care Med 1995; 151: 1821-1826.
13. Washington AV, et al. TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans. J Clin Invest 2009; 119: 1489-1501.
14. de Stoppelaar SF, et al. Protease activated receptor 4 limits bacterial growth and lung pathology during late stage Streptococcus pneumoniae induced pneumonia in mice. Thromb Haemost 2013; 110: 582-592.
15. Washington AV, et al. A TREM family member, TLT-1, is found exclusively in the alpha-granules of megakaryocytes and platelets. Blood 2004; 104: 1042-1047.
16. Adamzik M, et al. Whole blood impedance aggregometry as a biomarker for the diagnosis and prognosis of severe sepsis. Crit Care 2012; 16: R204.
17. Lundahl TH, et al. Impaired platelet function correlates with multi-organ dysfunction. A study of patients with sepsis. Platelets 1998; 9: 223-225.
18. Yaguchi A, et al. Platelet function in sepsis. J Thromb Haemost 2004; 2: 2096-2102.
19. Levi M, Schultz M. Coagulopathy and platelet disorders in critically ill patients. Minerva Anestesiol 2010; 76: 851-859.
20. Akca S, et al. Time course of platelet counts in critically ill patients. Crit Care Med 2002; 30: 753-756.
21. Moreau D, et al. Platelet count decline: an early prognostic marker in critically ill patients with prolonged ICU stays. Chest 2007; 131: 1735-1741.
22. Katz JN, et al. Beyond thrombosis: the versatile platelet in critical illness. Chest 2011; 139: 658-668.
23. De Blasi RA, et al. Immature platelet fraction in predicting sepsis in critically ill patients. Intensive Care Med 2012; 39: 636-643.
24. Ogura H, et al. Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma 2001; 50: 801-809.
25. Janiszewski M, et al. Platelet-derived exosomes of septic individuals possess proapoptotic NAD(P)H oxidase activity: A novel vascular redox pathway. Crit Care Med 2004; 32: 818-825.
26. Thery C, et al. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002; 2: 569-579.
27. Flaumenhaft R, et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood 2009; 113: 1112-1121.
28. Reid VL, Webster NR. Role of microparticles in sepsis. Br J Anaesth 2012; 109: 503-513.
29. Del Conde I, et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201: 871-879.
30. Azevedo LC, et al. Platelet-derived exosomes from septic shock patients induce myocardial dysfunction. Crit Care 2007; 11: R120.
31. Kuckleburg CJ, et al. Endothelial cell apoptosis induced by bacteria-activated platelets requires caspase-8 and-9 and generation of reactive oxygen species. Thromb Haemost 2008; 99: 363-372.
32. Burnier L, et al. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101: 439-451.
33. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
34. Linden MD. Platelet physiology. Methods Mol Biol 2013; 992: 13-30.
35. Markiewski MM, et al. Complexity of complement activation in sepsis. J Cell Mol Med 2008; 12: 2245-2254.
36. Peerschke EI, et al. Platelet activation by C1q results in the induction of alpha IIb/beta 3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity. J Exp Med 1993; 178: 579-587.
37. Arman M, et al. Amplification of bacteria-induced platelet activation is triggered by FcgammaRIIA, integrin alphaIIbbeta3 and platelet factor 4. Blood 2014; Epub ahead of print.
38. Cox D, et al. Platelets and the innate immune system: mechanisms of bacterialinduced platelet activation. J Thromb Haemost 2011; 9: 1097-1107.
39. Kerrigan SW, Cox D. Platelet-bacterial interactions. Cellular and molecular life sciences: CMLS 2010; 67: 513-523.
40. Panigrahi S, et al. Engagement of platelet toll-like receptor 9 by novel endogenous ligands promotes platelet hyperreactivity and thrombosis. Circulation Res 2013; 112: 103-112.
41. Andonegui G, et al. Platelets express functional Toll-like receptor-4. Blood 2005; 106: 2417-2423.
42. Shiraki R, et al. Expression of Toll-like receptors on human platelets. Thrombosis Res 2004; 113: 379-385.
43. Clark SR, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007; 13: 463-469.
44. Medzhitov R, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2: 253-258.
45. Semeraro F, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 2011; 118: 1952-1961.
46. McDonald B, et al. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 2012; 12: 324-333.
47. Blair P, et al. Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circulation Res 2009; 104: 346-354.
48. Keane C, et al. Invasive Streptococcus pneumoniae trigger platelet activation via Toll-like receptor 2. J Thromb Haemost 2010; 8: 2757-2765.
49. Montrucchio G, et al. Mechanisms of the priming effect of low doses of lipopoly-saccharides on leukocyte-dependent platelet aggregation in whole blood. Thromb Haemost 2003; 90: 872-881.
50. Zhang G, et al. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol 2009; 182: 7997-8004.
51. Coppinger JA, Maguire PB. Insights into the platelet releasate. Curr Pharm Design 2007; 13: 2640-2646.
52. Wijten P, et al. High precision platelet releasate definition by quantitative reversed protein profiling-brief report. Arterioscl Thromb Vasc Biol 2013; 33: 1635-1638.
53. White GC, Rompietti R. Platelet secretion: indiscriminately spewed forth or highly orchestrated? J Thromb Haemost 2007; 5: 2006-2008.
54. Wong HR, et al. Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children. Crit Care 2012; 16: R213.
55. Hamzeh-Cognasse H, et al. Contribution of activated platelets to plasma IL-27 levels. Crit Care 2013; 17: 411.
56. Lindemann S, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154: 485-490.
57. Rondina MT, et al. The septic milieu triggers expression of spliced tissue factor mRNA in human platelets. J Thromb Haemost 2011; 9: 748-758.
58. Hu JY, et al. Altered proteomic pattern in platelets of rats with sepsis. Blood Cells Mol Dis 2012; 48: 30-35.
59. Cecchetti L, et al. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood 2011; 118: 1903-1911.
60. Freishtat RJ, et al. Sepsis alters the megakaryocyte-platelet transcriptional axis resulting in granzyme B-mediated lymphotoxicity. Am J Resp Crit Care Med 2009; 179: 467-473.
61. Ple H, et al. Alteration of the platelet transcriptome in chronic kidney disease. Thromb Haemost 2012; 108: 605-615.
62. Etulain J, et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. Thromb Haemost 2012; 107: 99-110.
63. Burstein SA. Cytokines, platelet production and hemostasis. Platelets 1997; 8: 93-104.
64. Boman HG. Peptide antibiotics and their role in innate immunity. Ann Rev Immunol 1995; 13: 61-92.
65. Trier DA, et al. Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release. Infect Immun 2008; 76: 5706-5713.
66. Drago L, et al. Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity. BMC Microbiol 2013; 13: 47.
67. Kraemer BF, et al. Novel anti-bacterial activities of beta-defensin 1 in human platelets: suppression of pathogen growth and signaling of neutrophil extracellular trap formation. PLoS Pathogens 2011; 7: e1002355.
68. Henn V, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
69. Slupsky JR, et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998; 80: 1008-1014.
70. May AE, et al. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 2002; 106: 2111-2117.
71. Brown GT, McIntyre TM. Lipopolysaccharide Signaling without a Nucleus: Kinase Cascades Stimulate Platelet Shedding of Proinflammatory IL-1 beta-Rich Microparticles. J Immunol 2011; 186: 5489-5496.
72. Cognasse F, et al. Donor platelets stored for at least 3 days can elicit activation marker expression by the recipient's blood mononuclear cells: an in vitro study. Transfusion 2009; 49: 91-98.
73. Diacovo TG, et al. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996; 88: 146-157.
74. Ploppa A, et al. Mechanisms of leukocyte distribution during sepsis: an experimental study on the interdependence of cell activation, shear stress and endothelial injury. Crit Care 2010; 14: R201.
75. Gawaz M, et al. Platelet activation and interaction with leucocytes in patients with sepsis or multiple organ failure. Eur J Clin Invest 1995; 25: 843-851.
76. Peters MJ, et al. Circulating platelet-neutrophil complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and intracellular killing. Br J Haematol 1999; 106: 391-399.
77. Assinger A, et al. Efficient phagocytosis of periodontopathogens by neutrophils requires plasma factors, platelets and TLR2. J Thromb Haemost 2011; 9: 799-809.
78. Haselmayer P, et al. TREM-1 ligand expression on platelets enhances neutrophil activation. Blood 2007; 110: 1029-1035.
79. Weber B, et al. TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance. PLoS Pathogens 2014; 10: e1003900.
80. Brinkmann V, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-1535.
81. Xiang B, et al. Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun 2013; 4: 2657.
82. Kitchens CS. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). Hematology 2009: 240-246.
83. Levi M, et al. Plasma and plasma components in the management of disseminated intravascular coagulation. Best Pract Res Clin Haematol 2006; 19: 127-142.
84. Goerge T, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood 2008; 111: 4958-4964.
85. Loria GD, et al. Platelets support a protective immune response to LCMV by preventing splenic necrosis. Blood 2013; 121: 940-950.
86. Secor D, et al. Impaired microvascular perfusion in sepsis requires activated coagulation and P-selectin-mediated platelet adhesion in capillaries. Intensive Care Med 2010; 36: 1928-1934.
87. Shibazaki M, et al. Complement-dependent accumulation and degradation of platelets in the lung and liver induced by injection of lipopolysaccharides. Infect Immun 1999; 67: 5186-5191.
88. Singer G, et al. Platelet recruitment in the murine hepatic microvasculature during experimental sepsis: role of neutrophils. Microcircul 2006; 13: 89-97.
89. Brown KA, et al. Neutrophils in development of multiple organ failure in sepsis. Lancet 2006; 368: 157-169.
90. Coopersmith CM, et al. Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. J Am Med Assoc 2002; 287: 1716-1721.
91. Haimovitz-Friedman A, et al. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med 1997; 186: 1831-1841.
92. Sharron M, et al. Platelets induce apoptosis during sepsis in a contact-dependent manner that is inhibited by GPIIb/IIIa blockade. PLoS One 2012; 7: e41549.
93. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004; 351: 159-169.
94. Singbartl K, et al. Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure. FASEB J 2001; 15: 2337-2344.
95. Singbartl K, Ley K. Leukocyte recruitment and acute renal failure. J Molecular Med 2004; 82: 91-101.
96. Tokes-Fuzesi M, et al. Microparticles and acute renal dysfunction in septic patients. J Crit Care 2013; 28: 141-147.
97. Matthay MA, et al. The acute respiratory distress syndrome. J Clin Invest 2012; 122: 2731-2740.
98. Grommes J, et al. Disruption of platelet-derived chemokine heteromers prevents neutrophil extravasation in acute lung injury. Am J Resp Crit Care Med 2012; 185: 628-636.
99. Idell S, et al. Platelet-specific alpha-granule proteins and thrombospondin in bronchoalveolar lavage in the adult respiratory distress syndrome. Chest 1989; 96: 1125-1132.
100. Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990; 75: 550-554.
101. Asaduzzaman M, et al. Platelets support pulmonary recruitment of neutrophils in abdominal sepsis. Crit Care Med 2009; 37: 1389-1396.
102. Rahman M, et al. Platelet-derived CD40L (CD154) mediates neutrophil upregulation of Mac-1 and recruitment in septic lung injury. Ann Surg 2009; 250: 783-790.
103. Zarbock A, Ley K. The role of platelets in acute lung injury (ALI). Front Biosci 2009; 14: 150-158.
104. Zarbock A, et al. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006; 116: 3211-3219.
105. Rahman M, et al. Metalloproteinases regulate CD40L shedding from platelets and pulmonary recruitment of neutrophils in abdominal sepsis. Inflamm Res 2012; 61: 571-579.
106. Pu Q, et al. Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endothelium in Escherichia coli endotoxin-induced shock. Crit Care Med 2001; 29: 1181-1188.
107. Taylor FB, et al. 7E3 F(ab')2, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coli. Blood 1997; 89: 4078-4084.
108. Evangelista V, et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost 2005; 94: 568-577.
109. Seidel M, et al. Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis. J Thromb Haemost 2009; 7: 1030-1032.
110. Lipcsey M, et al. Early endotoxin-mediated haemostatic and inflammatory responses in the clopidogrel-treated pig. Platelets 2005; 16: 408-414.
111. Derhaschnig U, et al. Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia. Platelets 2010; 21: 320-328.
112. Eisen DP, et al. Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis. Crit Care Med 2012; 40: 1761-1767.
113. Erlich JM, et al. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest 2011; 139: 289-295.
114. Kor DJ, et al. Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med 2011; 39: 2393-2400.
115. Winning J, et al. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med 2010; 38: 32-37.
116. Winning J, et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets 2009; 20: 50-57.
117. Valerio-Rojas JC, et al. Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: a historical cohort study. Crit Care Res Pract 2013; 2013: 782573.
118. Gross AK, et al. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombol 2013; 35: 147-154.
119. Storey RF, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2013; Epub ahead of print.
120. Baughman RP, et al. Thrombocytopenia in the intensive care unit. Chest 1993; 104: 1243-1247.
121. Boldt J, et al. Platelet function in critically ill patients. Chest 1994; 106: 899-903.